ClinicalTrials.gg
RecruitingNCT06500780EQUIPDUpdated Jun 9, 2026

Equipping Patients Using Interventions for Pain and Depression

An interventional study of Coaching and Decision Aid in Chronic Pain, Musculoskeletal Pain and Depression, sponsored by Indiana University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.

Sponsored by Indiana University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
304
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,283 studies in Chronic Pain with a site in United States — 257 open to participants now, 348 under way, 7 of them phase 3. Chronic Pain · United States.

Planned enrollment
120th of 1,092
304 · median 60
Started
2024
with 102 others
No phase
803 of 1,283
168 open now
Primary completion
2027-05
later than 176 of 347 live
Registered
1,091st of 1,283
by date

Among the 1,283 studies in Chronic Pain with a site in United States, this one is the 120th largest by planned enrollment of the 1,092 interventional ones that give a count, is one of 103 that started in 2024, is one of 803 with no phase, reaches primary completion later than 176 of the 347 other live ones, and was the 1,091st registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

257 of the 1,283 studies in Chronic Pain with a site in United States are open now. Recruiting first, the newest first:

252 more — sign in →

All 257 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,283 studies in Chronic Pain with a site in United States, or all of them as a file.
02

Study summary

This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/). This randomized controlled trial (RCT) is phase 2 of a two-phase, 5-year project with the overarching goal of testing a decision aid (DA)/coaching intervention, tailored to Black patients with comorbid chronic pain and depression, to encourage use of and adherence to nonpharmacological pain treatments (NPTs).

This 2-arm trial will randomize 304 patients with comorbid chronic musculoskeletal pain and depression in primary care from an urban safety-net health system (Eskenazi). After the baseline assessment, patients randomized to the intervention will be asked to participate in 4 coaching sessions over approximately 12 weeks. Sessions will use Motivational Interviewing principles to foster openness to NPTs and self-efficacy by helping patients identify their goals and priorities, understand their NPT options, prepare them to discuss and choose options with their primary care providers (PCPs), and reinforce these choices to foster maintenance of these changes. DA contents will be integrated into these sessions, which will facilitate discussion of these options with their PCP. The first 3 sessions take place prior to the patient's next scheduled PCP visit; the final session occurs after this visit. Assessments will be conducted at baseline, 3 months (i.e., after completing the final coaching session), and 6 months.

Patients randomized to the wait-list control group will receive usual care (in addition to study assessments at baseline, 3 months, and 6 months). After completing the final assessment, they will then be given the DA and offered a 20-minute coaching session to walk them through it.

03

Conditions studied

  • Chronic Pain
  • Musculoskeletal Pain
  • Depression
  • Health Equity

Keywords

  • chronic pain
  • depression
  • health equity
  • shared decision making
  • decision aid
  • depressive symptoms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Eligible patients must

  • have musculoskeletal pain in the low back, cervical spine, or extremities (hip, knee, shoulder) for ≥3 months,
  • have at least moderate pain intensity and interference with function, defined by a score ≥4 (possible range: 0-10) on the Pain, Enjoyment of Life and General Activity scale (PEG), a 3-item measure of pain intensity, interference with enjoyment of life, and interference with general activity,
  • have at least mild depression, defined as PHQ-8 score ≥5,
  • identify as Black or African American,
  • have consistent access to a telephone,
  • indicate openness to new pain treatments, and
  • have a scheduled appointment with their PCP in the next approximate 2-4 months or be willing to schedule one

Exclusion criteria

Exclusion Criteria:

Patients are excluded:

  • if previously participated in Dr. Matthias' past pilot study (IRB #12885), the pilot RCT for this project (IRB #16571), or are participating as a Patient Engagement Panel member for this project (Aim 1.1),
  • if the eligibility screener or medical records indicate severe medical conditions likely precluding participation (e.g. stroke in the last 6 months, hospitalized with congestive heart failure or a heart attack in the last 6 months, cancer other than skin cancer and receiving active treatment), or
  • if the eligibility screener or medical records reveal (1) active suicidal ideation, or (2) severe hearing/speech or cognitive impairment.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
304 participants (estimated)

Study arms

  • Experimental
    Coaching and Decision Aid

    Intervention group (Individual coaching sessions and Decision Aid)

    Behavioral: Coaching and Decision Aid

  • No intervention
    Control

    Wait-list control group

Interventions

  • BehavioralCoaching and Decision Aid

    Four (4) coaching sessions over approximately 12 weeks with integration of Decision Aid contents

06

What researchers measure

Primary outcomes

  1. Change from Baseline Brief Pain Inventory (BPI) Interference Scale at 3 months

    The pain interference score averages seven ratings, 0 (does not interfere) to 10 (completely interferes).

    Time frame: 3 months

  2. Change from Baseline Brief Pain Inventory (BPI) Interference Scale at 6 months

    The pain interference score averages seven ratings, 0 (does not interfere) to 10 (completely interferes).

    Time frame: 6 months

  3. Change from Baseline Patient Health Questionnaire (PHQ)-8 at 3 months

    The Patient Health Questionnaire (PHQ)-8 is a widely-used, validated 8-item measure of depression severity that uses a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day).

    Time frame: 3 months

  4. Change from Baseline Patient Health Questionnaire (PHQ)-8 at 6 months

    The Patient Health Questionnaire (PHQ)-8 is a widely-used, validated 8-item measure of depression severity that uses a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day).

    Time frame: 6 months

Secondary outcomes

  1. Change from Baseline Generalized Anxiety Disorder (GAD)-7 at 3 months

    Anxiety will be measured with the 7 item Generalized Anxiety Disorder (GAD)-7 that uses a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day).

    Time frame: 3 months

  2. Change from Baseline Generalized Anxiety Disorder (GAD)-7 at 6 months

    Anxiety will be measured with the 7 item Generalized Anxiety Disorder (GAD)-7 that uses a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day).

    Time frame: 6 months

  3. Change from Baseline Pain Catastrophizing Scale at 3 months

    The Pain Catastrophizing Scale is a 13-item scale that assesses catastrophizing-a cognitive-emotional factor that predicts poor treatment response. The scale uses a 5-point Likert scale ranging from 0 (not at all) to 4 (all the time).

    Time frame: 3 months

  4. Change from Baseline Pain Catastrophizing Scale at 6 months

    The Pain Catastrophizing Scale is a 13-item scale that assesses catastrophizing-a cognitive-emotional factor that predicts poor treatment response. The scale uses a 5-point Likert scale ranging from 0 (not at all) to 4 (all the time).

    Time frame: 6 months

  5. Change from Baseline Use of Nonpharmacological and Self-Care Approaches (NSCAP) at 3 months

    The NSCAP asks about 9 nonpharmacological treatment (NPT) modalities and assesses details of use such as frequency, location/source of service, and patients' judgments of effectiveness. Space is also provided for other NPTs that are used but not listed. The number of modalities for which patients answer "yes" will be summed for analyses.

    Time frame: 3 months

  6. Change from Baseline Use of Nonpharmacological and Self-Care Approaches (NSCAP) at 6 months

    The NSCAP asks about 9 nonpharmacological treatment (NPT) modalities and assesses details of use such as frequency, location/source of service, and patients' judgments of effectiveness. Space is also provided for other NPTs that are used but not listed. The number of modalities for which patients answer "yes" will be summed for analyses.

    Time frame: 6 months

  7. Change from Baseline Altarum Consumer Engagement (ACE) Measure at 3 months

    Patient engagement will be measured with the 12-item Altarum Consumer Engagement (ACE) Measure, which has 3 subscales: 1) commitment to manage one's health, 2) informed choice, and 3) confidence to participate in treatment decisions. Items are assessed on a 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree).

    Time frame: 3 months

  8. Change from Baseline Altarum Consumer Engagement (ACE) Measure at 6 months

    Patient engagement will be measured with the 12-item Altarum Consumer Engagement (ACE) Measure, which has 3 subscales: 1) commitment to manage one's health, 2) informed choice, and 3) confidence to participate in treatment decisions. Items are assessed on a 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree).

    Time frame: 6 months

  9. Change from Baseline Decisional Conflict Scale (DCS) at 3 months

    Decisional conflict will be measured with the 16-item Decisional Conflict Scale that measures personal perceptions of a) uncertainty in choosing options, b) modifiable factors contributing to uncertainty, and c) effective decision making on a 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree).

    Time frame: 3 months

  10. Change from Baseline Decisional Conflict Scale (DCS) at 6 months

    Decisional conflict will be measured with the 16-item Decisional Conflict Scale that measures personal perceptions of a) uncertainty in choosing options, b) modifiable factors contributing to uncertainty, and c) effective decision making on a 5-point Likert scale ranging from 0 (strongly disagree) to 4 (strongly agree).

    Time frame: 6 months

Other outcomes

  1. Change from Baseline Perceived Efficacy in Patient-Physician Interactions Scale (PEPPI-5) at 3 months

    Communication self-efficacy will be measured with this 5-item scale that measures patients' self-efficacy in obtaining medical information and getting their most important health concern discussed in a clinic visit. The scale uses ratings from 0 (not at all confident) to 10 (extremely confident).

    Time frame: 3 months

  2. Change from Baseline Perceived Efficacy in Patient-Physician Interactions Scale (PEPPI-5) at 6 months

    Communication self-efficacy will be measured with this 5-item scale that measures patients' self-efficacy in obtaining medical information and getting their most important health concern discussed in a clinic visit. The scale uses ratings from 0 (not at all confident) to 10 (extremely confident).

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Eskenazi Health Primary Care
    Indianapolis, Indiana 46254, United States
    Recruiting
    • Research Specialist · Contactequipd@regenstrief.org · 317-274-9402
    • Adam T Hirsh, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — NIH intends to maximize the impact of HEAL Initiative-supported projects through broad and rapid data sharing. All HEAL Initiative award recipients, regardless of the amount of direct costs requested for any one year, are required to comply with the HEAL Public Access and Data Sharing Policy, which also aligns with the NIH Policy for Data Management and Sharing (https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-013.html). HEAL award recipients must following all requirements and timelines developed through the HEAL Initiative Data Ecosystem, as described in HEAL's compliance guidance (https://heal.nih.gov/data/complying-heal-data-sharing-policy).

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: At the time of publication of the primary manuscript

Access criteria: Implementation of the plan will follow the HEAL Public Access and Data Sharing Policy.

Data sharing details ↗ · heal.nih.gov

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for May 2027, 33 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 33 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Jul 15, 2024
StartActual
Aug 13, 2024
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Jun 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06500780
Lead sponsor
Indiana University
Responsible party
Adam Todd Hirsh (Professor, Indiana University) — Principal investigator
First posted
Jul 15, 2024
Start date
Aug 13, 2024
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 9, 2026

Study contacts

Research Specialist
Contact
equipd@regenstrief.org
317-274-9402
Jennifer Garabrant
Contact
jwilkers@iu.edu
317-278-2510
Adam T Hirsh, PhD
principal investigator · Indiana University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion